Stocks Buzz: Banco Bilbao Vizcaya Argentaria SA, National Bank of Greece, Majesco Entertainment Co, Array Biopharma Inc

Lakeway, TX -- (SBWIRE) -- 02/26/2013 -- vb-news.net, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Banco Bilbao Vizcaya Argentaria SA (ADR) (NYSE:BBVA) shares fell 7.72% and closed at $9.33. The company, on Feb. 1, announced that it has reached an agreement (the "Agreement") with MetLife, Inc, for the sale of the 64.3% share capital that BBVA holds in the Chilean pension fund manager "Administradora de Fondos de Pensiones Provida S.A.' ("AFP Provida" or the "Company").

How Should Investors Trade BBVA After The Solid Jump? Let’s Find Out Here

National Bank of Greece (ADR) (NYSE:NBG) shares fell 7.41% to $1.25. Reuters reported that National Bank of Greece SA on February 13, 2013 said it would cut up to 2,000 jobs, or about 15% of its workforce, to generate savings from its acquisition of smaller rival Eurobank. The cuts will target employees that are close to retirement and will be carried out on a voluntary basis, the bank said. They will be completed by March and will only affect National Bank employees, said a bank executive who declined to be named.

Is NBG Ready To Jump Again After The Solid Momentum? Get Free Trend Analysis Here

Majesco Entertainment Co. (NASDAQ:COOL) shares fell 7.64% and closed at $0.556 in the last trading session. On February 15, Majesco entered into the Second Amendment with Nintendo (NTDOY) of America, to the Confidential License Agreement for the Wii Console (Western Hemisphere), effective February 21, 2007, by and between Nintendo and the Company. The Second Amendment is effective on February 20 and was entered into to extend the term of the Agreement to February 20, 2016. All other terms and conditions of the Agreement, as previously disclosed, remain in full force and effect.

Is COOL Buy After The Recent Price Movement? Find Out Here

Array Biopharma Inc (NASDAQ:ARRY) shares declined 7.13% to $3.78. In a press release recently Array BioPharma said that during 2013, the company expects to make substantial progress in generating data to inform registration study decisions for our wholly-owned hematology programs, ARRY-520 and ARRY-614. Array-invented MEK162 will be tested in a Phase 3 trial in NRAS melanoma which is scheduled to start in April 2013, as well as BRAF mutant melanoma later in 2013 (with Novartis (NVS).

Is ARRY a Buy At The Current Market Price? Don’t Miss Out Our Special Coverage Here

About vb-news.net
vb-news.net’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by vb-news.net is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. vb-news.net does expect that investors will buy and sell securities based on information assembled and presented in vb-news.net. PLEASE always do your own due diligence, and consult your financial advisor.